Table 1: Comparison of the distribution of clinical and pathologic factors in men selected for bilateral or unilateral versus non-nerve sparing radical prostatectomy.

Clinical factorNon-nerve sparing (non-NS) 
Unilateral nerve sparing (UNS) 
Bilateral nerve sparing (BNS) 
value comparing non-NS, UNS, and BNS

Median PSA (IQR) (ng/mL)4.6 [4.0, 10.0]5.0 [4.0, 6.2]4.6 [3.5, 6.0]0.137
Median PPB (IQR) (%)50.0 [18.2, 70.0]33.3 [25.0, 50.0]16.7 [10.0, 25.0]<0.0001
PSA and PPB category*
 Both > median8 (10.39%)50 (64.94%)19 (24.68%)<0.0001**
 PSA > median
 PPB ≤ Median
1 (1.04%)30 (31.25%)65 (67.71%)<0.0001**
 PSA ≤ median
 PPB > median
5 (6.25%)49 (61.25%)26 (32.50%)<0.0001**
 Both ≤ median5 (4.81%)22 (21.15%)77 (74.04%)<0.0001**
Median age (IQR) (yrs)60.2 [52.0, 67.2]61.4 [57.4, 64.9]57.8 [52.9, 61.9]<0.0001
AJCC clinical tumor category <0.0001**
 1c16 (84%)109 (72%)170 (91%)
 2-33 (16%)42 (28%)17 (9%)
Biopsy Gleason score <0.0001**
 7 or less11 (58%)131 (87%)187 (100%)
 8 to 108 (42%)20 (13%)0 (0%)
AJCC prostatectomy tumor category <0.0001**
 212 (63%)119 (79%)174 (93%)
 3-47 (37%)32 (21%)13 (7%)
Prostatectomy Gleason score <0.0001**
 7 or less13 (68%)129 (85%)187 (100%)
 8–106 (32%)22 (15%)0 (0%)
Margin status<0.0001**
 Positive 8 (42%)18 (12%)10 (5%)
 Negative11 (58%)133 (88%)177 (95%)

PSA: prostate-specific antigen; PPB: percentage of positive prostate biopsies; IQR: interquartile range; AJCC: American Joint Commission on Cancer. *Overall, median PPB = 25%; overall, median PSA = 4.8 ng/mL; overall, 7% had PSA ≥ 10 ng/mL. **Fisher exact test value.